Alerta

Reagent for detecting long fragment deletion mutation of FHOD3 gene and application thereof

Resumen de: CN122168748A

The invention discloses a reagent for detecting long fragment deletion mutation of an FHOD3 gene and application of the reagent, and belongs to the technical field of biological medicines. The reagent comprises a nucleic acid molecule for specifically recognizing deletion mutation of a long fragment in an intron starting region of the FHOD3 gene, and particularly a primer and a probe aiming at deletion mutation of No.12-No.14 exons and/or deletion mutation of No.15 exons. The invention discovers and verifies the two pathogenic deletion mutations closely related to hypertrophic cardiomyopathy for the first time. By matching with a micro-droplet digital PCR technology, the sensitivity of the reagent reaches 99%, the specificity reaches 95% or above, the repeatability is good, and the accuracy reaches 95%-99%. The new detection rate in the patient family with negative whole exome sequencing in the past reaches 40%, the defect that the long fragment deletion of the intron starting region cannot be detected in the prior art is effectively overcome, and the method is suitable for gene diagnosis, family genetic screening and genetic counseling of hypertrophic cardiomyopathy.

Application of Enoph1 in treatment and/or diagnosis of cardiomyopathy or heart failure

Resumen de: CN122168744A

The invention relates to the technical field of biological medicines, in particular to application of Enoph1 in treatment and/or diagnosis of cardiomyopathy or heart failure. The application finds that the expression level of Enoph1 in patients with cardiomyopathy or heart failure is remarkably up-regulated. Furthermore, overexpression of Enoph1 in myocardial cells finds that overexpression of Enoph1 can recover the number of myocardial cells, glycolysis of myocardial cells, oxygen breathing function and mitochondrial function, reduce generation of active oxygen, protect myocardial cells and achieve the effect of treating cardiomyopathy or heart failure.

Biomarkers for risk prediction of idiopathic pulmonary hypertension and application of biomarkers

Resumen de: CN122168747A

The invention belongs to the technical field of biology, and discloses a group of biomarkers for risk prediction of idiopathic pulmonary hypertension and application of the biomarkers. According to the method, expression quantitative trait locus (eQTL) data from peripheral blood and lung tissue, a single-cell RNA sequencing (scRNA-seq) data set and whole genome association analysis (GWAS) summarized statistical data of idiopathic pulmonary hypertension are integrated, and a Mendel randomization algorithm (MR), genome enrichment analysis and immunofluorescence experiments are used for identifying and accurately positioning related genes; biomarkers related to the risk of idiopathic pulmonary hypertension, including at least one of CST7, HLA-B, HLA-E, FKBP1A, and UBB, have been found for the first time. By detecting the biomarker, the risk condition of idiopathic pulmonary hypertension can be effectively diagnosed.

Application of valeryl carnitine in prevention and treatment of progress of salt-sensitive hypertension state

Resumen de: CN122171695A

The invention provides an application of valeryl carnitine in preventing and treating the progress of a salt-sensitive hypertension state. The invention provides application of acyl carnitine, especially valeryl carnitine, in a sample from an individual as a target spot in screening and/or preparing a reagent and/or a medicine for preventing and treating salt-sensitive hypertension. The invention also provides application of the acyl carnitine or a reagent for detecting the acyl carnitine in a sample from an individual in preparation of a product for evaluating the progress of the blood pressure state of the individual, and application of the acyl carnitine in preparation of a product for improving, preventing and/or treating salt-sensitive hypertension. The acylcarnitine is found to be remarkably related to hypertension attack and blood pressure state progress, and is expected to become a potential dietary supplement or intervention target for preventing and treating hypertension.

METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION

Resumen de: US20260151373A1

0000 The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β<1 >adrenergic receptor gene.

Application of PTPRM in treatment and/or prevention of sepsis cardiomyopathy

Resumen de: CN122124244A

The invention relates to the technical field of biological medicines, in particular to application of PTPRM in treatment and/or prevention of sepsis cardiomyopathy. The application discovers that the expression level of PTPRM in heart tissue of a CLP model is remarkably reduced, and further verifies that the survival rate of the CLP model is remarkably improved after PTPRM overexpression, PAT reduction and RVFW, RVSFW, LVSFW, LVDFW, IVS-s and IVS-d increase caused by CLP modeling are also improved, in addition, the expression level of cardiac troponin (cTNT) and right ventricular wall thickness can also be reduced by overexpression of PTPRM, and the survival rate of the CLP model is remarkably improved. PTPRM can be used as a target spot for treating sepsis cardiomyopathy.

Venous thrombosis risk gene detection kit based on LAMP (loop-mediated isothermal amplification) technology

Resumen de: CN122128425A

The invention relates to the technical field of gene polymorphism detection, and discloses a venous thrombosis risk gene detection kit based on an LAMP (loop-mediated isothermal amplification) technology, which comprises primer probes used for detecting venous thrombosis risk gene polymorphism sites, detection reaction system components, a reagent A, a reagent B, a positive quality control A, a positive quality control B and a negative control, the reagent A and the reagent B respectively comprise matched primer probes and detection reaction system components, the reagent A is a 4G reaction tube, a C reaction tube, an AAG reaction tube, a G reaction tube or a T reaction tube, and the reagent B is a corresponding 5G reaction tube, a T reaction tube, a del reaction tube, an A reaction tube or a C reaction tube. According to the invention, reactions of different nucleic acid sequences are physically isolated in the independent reagent A and reagent B so as to avoid mutual interference of primer probes, meanwhile, polymerase and cresol red are utilized to convert system component change into color change, and visual output and accurate typing of multi-target amplification signals are synchronously realized under the condition of avoiding instrument assistance.

Application of KLF13 gene regulatory factor in great vessel arteriovenous senescence

Resumen de: CN122128418A

The invention belongs to the technical field of biomedicine, and discloses application of a KLF13 gene regulatory factor in great vessel arteriovenous senescence. Systematic analysis on a Klf13 gene knockout mouse shows that Klf13 is an important protection factor for maintaining the vascular homeostasis. In-vitro experiments show that the DNA damage of KLF13 knock-down cells is increased, the multiplication capacity is reduced, and the KLF13 plays a role in protecting blood vessel aging; in vascular cell types, the change of KLF13 knock-down in endothelial cells is most significant. Arteriovenous endothelium migration and tubulation function decline. The core function of KLF13 in maintaining the steady state of the blood vessel is disclosed. According to the discovery, the status of KLF13 serving as a key vascular protection factor is determined from the functional level, and dysfunction of KLF13 may be closely related to occurrence and development of vascular aging and related diseases. And theoretical and practical basis is provided for developing products for identifying senescence of vascular cells.

Plasma protein as biomarker for diagnosing STEMI combined hypertension and application

Resumen de: CN122128427A

The invention discloses a plasma protein as a biomarker for diagnosing STEMI combined hypertension and application thereof, and is characterized in that the plasma protein biomarker is CA1 and can be applied to preparation of a product for diagnosing STEMI combined hypertension; the kit has the advantages that the STEMI combined hypertension is diagnosed in an early stage by measuring the plasma protein biomarkers, an effective tool is provided for diagnosis of the STEMI combined hypertension, the detection efficiency is high, and the pertinence is strong.

Single or combined gene marker of GFPT2, LUM, TNXB and THBS4 and application of gene marker in risk early warning and prognosis evaluation of cardiovascular diseases

Resumen de: CN122104891A

The invention provides a single or combined gene marker of GFPT2, LUM, TNXB and THBS4 and application of the gene marker in risk early warning and prognosis evaluation of cardiovascular diseases, and belongs to the technical field of biomedicine. The invention provides a universal molecular marker composition which is closely associated with a common core pathological mechanism (namely myocardial fibrosis) finally causing heart failure, and the universal molecular marker composition can cross the initial causes of different cardiovascular diseases and can be used for detecting the heart failure in the early stage of irreversible fibrosis damage of myocardium. Accurate early warning and prognosis evaluation of the heart failure risk are realized, and a time window and a targeting basis are provided for early intervention. The invention finds that the four genes GFPT2, LUM, TNXB and THBS4 can be independently used or a combination of the four genes can be used as a universal biomarker for crossing different causes and specifically pre-warning a common end pathway (myocardial fibrosis) of heart failure. The invention establishes a heart failure risk prediction mathematical model which is based on the expression levels of the four genes and is suitable for wide cardiovascular patient groups.

BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF

Resumen de: US20260148848A1

0000 The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma/Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS BY INHIBTION OF ANNEXIN A8

Resumen de: EP4748932A1

The present invention refers to Annexin A8 (AnxA8) inhibitors, or pharmaceutical composition comprising thereof, for use in a method for the treatment and/or prevention of atherosclerosis. Preferably, the method comprises preventing atherosclerotic plaque formation.

Application of reagent for inhibiting or detecting Fasn and medicine for preventing and/or treating transplanted vascular remodeling

Resumen de: CN122075518A

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and/or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and/or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal/medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

Reagent and kit for dilated cardiomyopathy diagnosis or risk assessment

Resumen de: CN122081474A

The invention belongs to the technical field of biological medicines, and discloses a new mutation c.311Ggt of a TNNT2 gene related to dilated cardiomyopathy. A. Family genetic analysis and in-vitro function verification prove that the mutation causes enhanced sensitivity of myocardial cells to doxorubicin and fragmentation of a mitochondrial network, and the mutation has pathogenicity. On the basis, the invention provides a specific detection primer pair and a kit, which are used for rapid gene diagnosis and risk assessment of dilated cardiomyopathy.

Biomarker UBE2L3 for poor collateral circulation and application thereof

Resumen de: CN122081482A

The invention provides a poor collateral circulation biomarker UBE2L3 and application thereof, and belongs to the technical field of biomedicine. According to the application disclosed by the invention, the key effect of the UBE2L3 in inhibiting the formation of the chronic coronary artery complete occlusion collateral circulation is defined for the first time, and the 'UBE2L3-Parkin-Drpl' axis is determined as a key endogenous inhibition pathway for regulating and controlling the CTO collateral circulation. The invention provides a clear intervention target with a clear mechanism for developing a brand new precise therapy for promoting therapeutic angiogenesis, solves the problems of unstable curative effect and off-target risk caused by a wide target in a current angiogenesis promoting strategy, provides a brand new non-surgical biological treatment strategy aiming at enhancing endogenous angiogenesis ability, and has a wide application prospect. Myocardial ischemia is expected to be improved essentially, so that the risk of adverse events such as long-term myocardial infarction and heart failure is reduced.

Application of carbonic anhydrase IV in prevention and treatment of coronary microangiopathy

Resumen de: CN122071740A

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of carbonic anhydrase IV in prevention and treatment of coronary microangiopathy. The research proves that the carbonic anhydrase IV has the effects of maintaining the activity of human microvascular endothelial cells, promoting the development of heart microvessels and protecting the barrier function of the microvessels. It is shown that the carbonic anhydrase IV can play a role in inhibiting CMVD lesion by preventing heart microvascular density reduction and inhibiting heart microvascular permeability increase in the CMVD process, and therefore the carbonic anhydrase IV has good potential practical application value.

MULTILINEAGE CARDIOVASCULAR ORGANOIDS AND METHODS OF GENERATING THE SAME

Resumen de: US20260139229A1

0000 Provided herein are multilineage cardiovascular organoids and methods of generating the same. In some aspects, provided herein is a system comprising a plurality of multilineage cardiovascular organoids derived from embryoid bodies. The embryoid bodies can be aggregated from pluripotent stem cells of varying genotypes. The multilineage cardiovascular organoids and systems described herein may be used for screening of agents, such as anti-cancer agents, for cardiotoxicity.

Kit for diagnosing acute myocardial infarction

Resumen de: CN122060858A

The invention provides a kit for diagnosing acute myocardial infarction, and belongs to the field of functions and application of genes. The kit comprises a primer pair used for detecting the expression quantity of the NEO-1 gene, a forward primer is SEQ ID NO.1, and a reverse primer is SEQ ID NO.2. By means of the primer pair, the expression quantity of the NEO-1 gene in peripheral blood can be detected, and compared with non-coronary heart disease patients, the expression of NEO-1 in peripheral blood of AMI patients is increased. The expression increase of NEO-1 is found to be an independent risk factor of AMI, and the expression quantity of NEO-1 in peripheral blood of an AMI patient can be used as one of biomarkers of AMI.

Application of CircWHSC1 as biomarker for invalid recanalization after ischemic stroke

Resumen de: CN122060855A

The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.

Biomarker and kit for diagnosing post-stroke depression qi deficiency and blood stasis and liver depression and qi stagnation syndromes

Nº publicación: CN122060852A 19/05/2026

Solicitante:

ZHEJIANG CHINESE MEDICAL UNIV
\u6D59\u6C5F\u4E2D\u533B\u836F\u5927\u5B66

Resumen de: CN122060852A

The invention discloses a biomarker and a kit for diagnosing post-stroke depression qi deficiency and blood stasis, liver depression and qi stagnation. The biomarker comprises Clcn3 and/or Nco7. According to the application, by constructing animal models with various diseases and combining ELISA and qPCR technologies, multi-dimensional verification is carried out on candidate targets, and expression changes of the candidate targets in the models are confirmed. Further, by drawing an ROC curve, the diagnostic efficiency (including AUC value, sensitivity and specificity) of each candidate marker is evaluated. Besides, an AAV-mediated RNA interference function experiment is comprehensively applied, a biomarker with diagnosis potential is deeply excavated, and a molecular basis is provided for objective diagnosis of syndromes.